The Zhitong Finance App learned that Daimo released a research report saying that Dongguang Pharmaceutical (01558)'s “increase in holdings” rating is believed to increase within 30 days. The probability of occurrence may reach 70%-80%. The target price is 12 Hong Kong dollars. The valuation is attractive. Recent data from the US Centers for Disease Control and Prevention (CDC) shows that H1N1, worsening influenza, has reappeared. As the main producer of the influenza antiviral drug “oseltamivir” in the mainland, there is a strong correlation between the company's profit and stock price performance and incidence data. The company's sharp stock-outs and increased production operations suggest that this year will see breakthrough sales growth.
大摩:予东阳光药(01558)“增持”评级 目标价12港元
Daimo: Yudong Sunshine Pharmaceutical (01558) “increase its holdings” rating target price is HK$12
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.